全文获取类型
收费全文 | 24600篇 |
免费 | 1993篇 |
国内免费 | 519篇 |
专业分类
耳鼻咽喉 | 146篇 |
儿科学 | 493篇 |
妇产科学 | 384篇 |
基础医学 | 2142篇 |
口腔科学 | 489篇 |
临床医学 | 2203篇 |
内科学 | 3496篇 |
皮肤病学 | 133篇 |
神经病学 | 1107篇 |
特种医学 | 793篇 |
外国民族医学 | 1篇 |
外科学 | 5894篇 |
综合类 | 3287篇 |
预防医学 | 2364篇 |
眼科学 | 295篇 |
药学 | 1827篇 |
11篇 | |
中国医学 | 972篇 |
肿瘤学 | 1075篇 |
出版年
2024年 | 29篇 |
2023年 | 370篇 |
2022年 | 870篇 |
2021年 | 1024篇 |
2020年 | 912篇 |
2019年 | 762篇 |
2018年 | 944篇 |
2017年 | 769篇 |
2016年 | 870篇 |
2015年 | 852篇 |
2014年 | 1793篇 |
2013年 | 1766篇 |
2012年 | 1477篇 |
2011年 | 1586篇 |
2010年 | 1226篇 |
2009年 | 1337篇 |
2008年 | 1254篇 |
2007年 | 1265篇 |
2006年 | 1120篇 |
2005年 | 972篇 |
2004年 | 768篇 |
2003年 | 608篇 |
2002年 | 553篇 |
2001年 | 482篇 |
2000年 | 479篇 |
1999年 | 419篇 |
1998年 | 331篇 |
1997年 | 298篇 |
1996年 | 274篇 |
1995年 | 253篇 |
1994年 | 233篇 |
1993年 | 193篇 |
1992年 | 142篇 |
1991年 | 138篇 |
1990年 | 100篇 |
1989年 | 91篇 |
1988年 | 90篇 |
1987年 | 65篇 |
1986年 | 59篇 |
1985年 | 59篇 |
1984年 | 51篇 |
1983年 | 25篇 |
1982年 | 40篇 |
1981年 | 16篇 |
1980年 | 27篇 |
1979年 | 25篇 |
1978年 | 26篇 |
1977年 | 13篇 |
1976年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
目的探讨经肝动脉灌注^131 I-HAbl8F(ab’)2治疗肝癌合并门脉癌栓的价值。方法8例合并门脉癌栓的晚期肝癌患者行经肝动脉超选择灌注^131 I-HAbl8F(ab')2临床治疗性试验,剂量:0.75mCi/kg。分析症状、卡氏评分、肝功能、AFP及肿瘤CT等影像变化,随访近期疗效。结果7例疼痛患者中,3例症状缓解。3例卡氏评分增加、4例稳定。6例AFP异常患者治疗后3例下降。全组病例用药后肝功能损害均无明显加重。1例无明显症状的弥漫型肝癌患者治疗后病灶减少;余7例中,瘤体增大5例、缩小2例,其中,PR2例,临床有效率28.6%。本组1例1年随访时生存。结论经肝动脉灌注0.75mCi/kg ^131 I-HAbl8F(ab')2对合并门脉癌栓的肝癌患者肝功影响小,对门脉分支癌栓患者有较好的疗效。 相似文献
83.
原发性肝癌患者肝切除术前、后免疫细胞表型分析 总被引:1,自引:1,他引:0
目的研究原发性肝癌(PrimaryLiverCarcinoma,PLC)患者肝切除术前、后免疫细胞表型的变化。方法采用直接免疫荧光标记,流量血细胞计数法(FlowCytometry,FCM)检测方法,动态观察120例PLC患者肝切除术前后外周血T淋巴细胞亚群、NK细胞和HLA鄄DR含量变化。结果肝切除术前肝功能Child鄄PughB级、OGTTL型和术前施行肝动脉栓塞化疗患者外周血CD8+T细胞含量明显低于正常人组,CD4+/CD8+比值则较高(P<0郾05)。全部肝癌患者肝切除术前、后CD3+CD4+T细胞和NK细胞(CD3-CD16+CD56+)含量无明显差异。术后第1天、第3天、第7天和第2周外周血淋巴细胞CD3+CD8+含量明显低于肝切除术前和术后第3周(P<0.01);而CD4+/CD8+比值则显著高于肝切除术前和术后第3周(P<0郾01)。结论PLC合并肝硬变肝储备功能不足、术前肝动脉栓塞化疗和肝切除术可导致机体细胞免疫功能低下,PLC患者肝切除术前行肝动脉栓塞化疗的价值有待深入研究。 相似文献
84.
The aim of this study was to evaluate whether a prevalent vertebral deformity predicts mortality and fractures in both men and women. In the city of Malmö, 598 individuals (298 men, 300 women; age 50–80 years) were selected from the city's population and were included in the Swedish part of the European Vertebral Osteoporosis Study (EVOS). At baseline the participants answered a questionnaire and lateral spine radiographs were performed. The prevalence of subjects with vertebral deformity was assessed using a morphometric method. The mortality during a 10-year follow-up period was determined through the register of the National Swedish Board of Health and Welfare. Eighty-five men and 43 women died during the study period. The subsequent fracture incidence during the follow-up period was ascertained by postal questionnaires, telephone interviews and by a survey of the archives of the Department of Radiology in the city hospital. Thirty-seven men and 69 women sustained a fracture during the study period. Data are presented as hazard ratios (HR) with 95% confidence interval (95% CI) within brackets. Prevalent vertebral deformity, defined as a reduction by more than 3 standard deviations (SD) in vertebral height ratio, predicted mortality during the forthcoming decade in both men [age-adjusted HR 2.4 (95% CI 1.6–3.9)] and women [age-adjusted HR 2.3 (95% CI 1.3–4.3)]. In men there was an increased mortality due to cardiovascular and pulmonary diseases and in women due to cancer. Prevalent vertebral deformity predicted an increased risk of any fracture during the forthcoming decade in both men [age-adjusted HR 2.7 (95% CI 1.4–5.3)] and women [age-adjusted HR 1.8 (95% CI 1.1–2.9)]. Prevalent vertebral deformity predicted an increased risk of any subsequent fragility fracture in women [age-adjusted HR 2.0 (95% CI 1.1–3.5)]; however, in men the increased risk was nonsignificant [age-adjusted HR 1.9 (95% CI 0.7–5.1)]. In summary, a prevalent vertebral deformity can predict both increased mortality and increased fracture incidence during the following decade in both men and women. We conclude that prevalent vertebral deformity could be used as a risk factor in both genders for mortality and future fracture. 相似文献
85.
目的:建立骨钙素酶免疫测定方法,并应用于临床检测血清骨钙素。方法:应用了3种检测模式,根据检测灵敏度、剂量反应曲线的形态进行分析,选择出合适的模式进一步应用于临床血清标本的骨钙素检测。结果:所采用的骨钙素单克隆抗体是钙离子依赖型的。固相抗原竞争法适合于临床定量测定骨钙素。最低可测限为1.4μg/L;20μg/L骨钙素样品批内CV=3.98%,批间CV=12.67%。测定正常献血员140名(年龄17-45岁),第5-95百分位点的骨钙素含量,男性为7.5-15.0μg/L女性为7.0-17.5μg/L。70例疑有骨质疏松症患者血清骨钙素含量2.91-30.20μg/L,以第95百分位点的骨钙素含量为cut-off值,升高5例。与进口试剂盒(Novocalcin,USA)相比较,有较好的相关性,r=0.81。结论:固相抗原竞争法酶免疫测定可以灵敏地检测血清中骨钙素含量,有实用价值。 相似文献
86.
Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage. 相似文献
87.
88.
双侧侧脑室外引流并脑脊液置换术治疗原发性脑室出血23例 总被引:2,自引:0,他引:2
我科自1995年1月至2005年1月共收治原发性脑室出血23例,经双侧侧脑室外引流并脑脊液置换术冶疗取得较好效果,现报道如下。 相似文献
89.
经皮椎体成形术治疗骨质疏松性胸腰椎压缩性骨折 总被引:11,自引:2,他引:9
[目的]观察经皮椎体成形术(PVP)治疗疼痛性高龄骨质疏松性胸腰椎压缩骨折的临床疗效。[方法]在C臂X线透视监控下,以骨水泥(PMMA)为充填材料,经单侧或双侧椎弓根穿刺行PVP治疗6例、脊柱后凸成行术治疗2例。[结果]术中无骨水泥渗漏,术后患者疼痛明显缓解或消失,无1例出现严重并发症。[结论]PVP治疗疼痛性高龄骨质疏松性胸腰椎压缩性骨折是安全、有效、经济的。 相似文献
90.
目的 探讨血清瘦素水平对老年男性骨质疏松的影响。方法 选取年龄在60-92岁的158例老年男性,采用双能X线法(DXA)检测骨密度,并根据测值将受试者分为骨质疏松组与非骨质疏松组,用放射免疫法(RIA)检测两组空腹血清瘦素浓度,进行比较研究。结果 血清瘦素测值在不同年龄组间的差异无统计学意义,而在肥胖组与非肥胖组间有显著差异(P〈0.01)。在老年男性骨质疏松组血清瘦素测值明显低于非骨质疏松组,两者具有显著差异(P〈0.05)。结论 血清瘦索测值并不随老年男性的年龄而变化。但与老年男性的体重指数呈正相关,血清瘦素对老年男性骨质疏松有较好的预示及保护作用。 相似文献